

What is already known on this topic

No systematic reviews have studied topical rubefaciants containing salicylates for the treatment of acute or chronic pain

A seeming lack of clinical trials may be partly due to lack of consensus on a definition for rubefaciants

What this study adds

Randomised double blind trials have studied topical salicylates in acute and chronic pain

Trials were limited by small size, inadequate design, and validity, making results tentative

Topical salicylate may have efficacy in acute pain at seven days but poor to moderate efficacy in chronic pain at 14 days

Better trials showed little difference from placebo

placebo gels were rubbed onto the skin in the same way as active treatments, we found that active treatments were significantly better than placebo.

Creating double blind conditions in trials of counter irritants can be problematic as rubefaciants irritate the skin whereas inactive placebos do not. Some studies allowed for this by removing the principle ingredient from the treatment, leaving a placebo vehicle containing some other potentially irritant ingredients. Although the number needed to treat for combined outcomes of trials of this type was greater (worse) than for trials with inactive placebo, the difference was not statistically significant and there was insufficient evidence to draw conclusions.

Contributors: See bmj.com

Funding: This work was supported by research funds from the Oxford Pain Relief Trust.

Competing interests: RAM and HJM have consulted for various pharmaceutical companies. RAM, HJM, and JE have received lecture fees from pharmaceutical companies related to analgesics and other healthcare interventions. All authors have received research support from charities, government, and industry sources at various times, but no such support was received for this work.

Ethical approval: Not required.

- 1 British Medical Association, Royal Pharmaceutical Society of Great Britain. *British national formulary*. London: BMA, RPS, 2003. (No 45.)
- 2 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nat New Biol* 1971; 231:232-5.
- 3 Morton I, Hall J. *The Royal Society of Medicine: medicines*. 6th ed. London: Bloomsbury, 2002.
- 4 Reynolds JEF, ed. *Martindale: the extra pharmacopoeia*. 32nd ed. London: Royal Pharmaceutical Society, 1999.
- 5 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1-12.
- 6 Cook D, Sackett DL. On the clinically important difference. *Ann Intern Med* 1992;117:A16-7.
- 7 Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG, eds. *Statistics with confidence—confidence intervals and statistical guidelines*. London: British Medical Journal, 1995:50-63.
- 8 L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. *Ann Intern Med* 1987;107:224-33.
- 9 Jadad AR, Carroll D, Moore A, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. *Pain* 1996;66:239-46.

- 10 Ginsberg F, Famaey JP. A double-blind study of topical massage with Rado-Salil ointment in mechanical low-back pain. *J Int Med Res* 1987;15:148-53.
- 11 Lester AA, Geller O, Bach GL, Fotiadis P. Management of sprained ankles. A double-blind study. *Practitioner* 1981;225:935-6.
- 12 Rothhaar J, Thiel W. Percutaneous gel therapy of blunt athletic injuries. *Med Welt* 1982;33:1006-10. (In German.)
- 13 Stam C, Bonnet MS, van Haselen RA. The efficacy and safety of a homeopathic gel in the treatment of acute low back pain: a multi-centre, randomised, double-blind comparative clinical trial. *Br Homeopath J* 2001;90:21-8.
- 14 Algozzine GJ, Stein GH, Doering PL, Araujo OE, Akin KC. Trolamine salicylate cream in osteoarthritis of the knee. *JAMA* 1982;247:1311-3.
- 15 Bach GL, Fotiadis P, Wanet G. Enelbin rheumatism ointment in rheumatic diseases. Results of a double-blind study for the determination of efficacy. *Fortschr Med* 1979;97:1249-52. (In German.)
- 16 Camus JP. Action de la myrtécaine associée au salicylate de diéthylamine, en traitement local, dans diverses affections rhumatismales. *Rheumatologie* 1975;27:61-6.
- 17 Rutner M, Fitzek J, Jahnel-Kracht H, Otto J, Krause W. Treatment of rheumatism with a hydroxyethylsalicylate gel. Results of 2 clinical studies of effectiveness and bioavailability. *Fortschr Med* 1995;113:111-3. (In German.)
- 18 Shackel NA, Day RO, Kellett B, Brooks PM. Copper-salicylate gel for pain relief in osteoarthritis: a randomised controlled trial. *Med J Aust* 1997;167:134-6.
- 19 Wanet G. Controlled clinical study of a topic associating noproxamine with diethylamine salicylate (Algesal suractive) in physical medicine and rehabilitation. *J Belge Med Phys Rehabil* 1979;2:119-26. (In French.)
- 20 Geller O, Bach GL, Fotiadis P. Comparison of a salicylate-heparin gel with a monosubstance preparation. Results of a double-blind cross-over study. *Munch Med Wochenschr* 1980;122:1231-2. (In German.)
- 21 Golden EL. A double-blind comparison of orally ingested aspirin and a topically applied salicylate cream in the relief of rheumatic pain. *Curr Ther Res* 1978;24:524-9.
- 22 Göttsche PC. Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. *Ann Rheum Dis* 2001;60:349-52.
- 23 Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions. A review of the literature. *Drugs* 1998;56:783-99.

(Accepted 20 February 2004)

doi 10.1136/bmj.38040.607141.EE

Corrections and clarifications

Intimate partner violence

In this editorial by Lorraine E Ferris (13 March, pp 595-6) we let a wrong reference number slip through. The reference number in the title of the box should be 9 (not 8, as we stated).

Smoking and blindness

In the "web extra" material for this editorial by Simon P Kelly and colleagues, we forgot to make some final small amendments that the authors had told us about (6 March, pp 537-8). In the third sentence of the section headed "sensitivity analysis," 61 800 should be 53 900 (consistent with elsewhere in the text and web extra material). The last part of the URL for the web reference W7 where it appears after the table (the second time it appears in the web extra material) is wrong; the correct URL is www.statistics.gov.uk/census2001/pop2001/united_kingdom.asp (as it appears in the list of web references).

This week in the BMJ: Children treated for heart conditions survive equally well across UK

We mixed up survival and mortality to produce a rather alarming sentence in this summary paragraph for the paper by John L Gibbs and colleagues ("Survival after surgery or therapeutic catheterisation for congenital heart disease in children in the United Kingdom: analysis of the central cardiac audit database for 2000-1," 13 March, pp 611-5). We also omitted the word infant. So the third sentence should read: "Infant mortality [not "Survival"] at one year was double that at 30 days and may be a better descriptor of overall outcome."